On April 23, 2026 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, reported its sales for the first quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q1 2026 % change % change
€m Actual CER
Oncology 707.5 8.0 % 13.0 %
Rare Disease 147.1 109.1 % 125.4 %
Neuroscience 220.3 13.8 % 18.5 %
Total Sales 1,074.9 17.0% 22.6%

"Ipsen has delivered a strong start to 2026," said David Loew, Chief Executive Officer, Ipsen. "We advanced our strategic priorities across the business, combining strong top‑line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients."

Full-year guidance 2026
Ipsen is confirming its financial guidance3 for full-year 2026:

Total sales growth greater than 13.0%, at constant currency, assuming accelerated sales growth of the portfolio excluding Somatuline and the growth of Somatuline sales due to generic lanreotide challenges. Based on the average level of exchange rates in March 2026, an adverse effect on total sales of around 1% of currencies is expected
Core operating margin greater than 35.0% of total sales
Upcoming 2026 milestones

Ipsen anticipates several key milestones across its portfolio in 2026, including:

Iqirvo (ELSPIRE trial) – Readout of pivotal Phase III in primary biliary cholangitis
Bylvay (BOLD trial) – Readout of pivotal Phase III in biliary atresia
Dysport (BEOND trials) – Readout of pivotal Phase III trials in chronic and episodic migraine
Corabotase (IPN10200, LANTIC trial) – Readout of Phase II in lateral canthal lines and forehead lines
Data from stage 1 of the Phase II LANTIC trial of corabotase (IPN10200) will be presented at the Music City SCALE (Symposium for Cosmetic Advances and Laser Education) 2026 symposium in May.

Pipeline update
On 30 January 2026, Ipsen expanded its pre‑clinical pipeline in rare neurodegenerative diseases through a global collaboration and exclusive option agreement with Origami Therapeutics. The partnership focuses on a research‑stage protein‑degrader program targeting genetic neurodegenerative diseases. Should Ipsen exercise its option following successful drug‑candidate nomination, the Company would assume full responsibility for global development and commercialization, reinforcing its strategy in rare neuroscience and first‑in‑class innovation.

On 9 March 2026, Ipsen announced the voluntary withdrawal of Tazverik (tazemetostat) from all indications and all Ipsen markets, effective immediately, following emerging safety data from the ongoing Phase Ib/III SYMPHONY‑1 trial in follicular lymphoma.

On 22 April 2026, following the positive European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion, Ipsen was granted conditional marketing authorization by the European Commission (EC) for Ojemda (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. Approval is based on the pivotal Phase II FIREFLY-1 data demonstrating meaningful and durable tumor responses.

Conference call

A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here.

Calendar

Ipsen intends to publish its half-year results on 30 July 2026.

Notes

All financial figures are in € millions (€m). The performance shown in this announcement covers the three-month period to 31 March 2026 (Q1 2026, the quarter), compared to the three-month period to 31 March 2025 (Q1 2025) unless stated otherwise.

(Press release, Ipsen, APR 23, 2026, View Source [SID1234664722])